The host interactome of influenza virus presents new potential targets for antiviral drugs

Reviews in Medical Virology

Volumn 21, Issue 6, 2011, Pages 358-369

  Shaw, Megan L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CD81 ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR5; COAT PROTEIN COMPLEX I; COATOMER PROTEIN; DAS 181; FLUDASE; GENE PRODUCT; HOST FACTOR; INTERLEUKIN 17 RECEPTOR; KARYOPHERIN BETA; MARAVIROC; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NUCLEOPORIN 98; OSELTAMIVIR; PERAMIVIR; PHOSPHOPROTEIN PHOSPHATASE 1; POLO LIKE KINASE 3; PROTEIN C JUN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RIMANTADINE; SMALL INTERFERING RNA; TG 003; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN; ZANAMIVIR;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS; NONHUMAN; REVIEW; RNA INTERFERENCE; RNA VIRUS; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE;

EID: 80055073333     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.703     Document Type: Review

References (45)

1. Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In Fields Virology, Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins: Philadelphia, 2007; 1647-1689.
2. Rust MJ, Lakadamyali M, Zhang F et al. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nature Structural and Molecular Biology 2004; 11: 567-573.
3. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry 2000; 69: 531-569.
4. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69: 517-528.
5. Cros JF, Garcia-Sastre A, Palese P. An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic 2005; 6: 205-213.
6. Li ML, Ramirez BC, Krug RM. RNA-dependent activation of primer RNA production by influenza virus polymerase: different regions of the same protein subunit constitute the two required RNA-binding sites. EMBO Journal 1998; 17: 5844-5852.
7. Fechter P, Brownlee GG. Recognition of mRNA cap structures by viral and cellular proteins. Journal of General Virology 2005; 86: 1239-1249.
8. Dias A, Bouvier D, Crepin T et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009; 458: 914-918.
9. Poon LL, Pritlove DC, Fodor E et al. Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template. Journal of Virology 1999; 73: 3473-3476.
10. Deng T, Vreede FT, Brownlee GG. Different de novo initiation strategies are used by influenza virus RNA polymerase on its cRNA and viral RNA promoters during viral RNA replication. Journal of Virology 2006; 80: 2337-2348.
11. Perez JT, Varble A, Sachidanandam R et al. Influenza A virus-generated small RNAs regulate the switch from transcription to replication. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 11525-11530.
12. O'Neill RE, Talon J, Palese P. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO Journal 1998; 17: 288-296.
13. Neumann G, Hughes MT, Kawaoka Y. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO Journal 2000; 19: 6751-6758.
14. Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 2005; 342: 215-227.
15. Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology 2011; 411: 229-236.
16. Palese P, Tobita K, Ueda M et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61: 397-410.
17. Hale BG, Randall RE, Ortin J et al. The multifunctional NS1 protein of influenza A viruses. Journal of General Virology 2008; 89: 2359-2376.
18. Garcia-Sastre A, Egorov A, Matassov D et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998; 252: 324-330.
19. Chen W, Calvo PA, Malide D et al. A novel influenza A virus mitochondrial protein that induces cell death. Nature Medicine 2001; 7: 1306-1312.
20. Conenello GM, Zamarin D, Perrone LA et al. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathogens 2007; 3: 1414-1421.
21. Brass AL, Huang IC, Benita Y et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139: 1243-1254.
22. Hao L, Sakurai A, Watanabe T et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008; 454: 890-893.
23. Karlas A, Machuy N, Shin Y et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010; 463: 818-822.
24. Konig R, Stertz S, Zhou Y et al. Human host factors required for influenza virus replication. Nature 2010; 463: 813-817.
25. Shapira SD, Gat-Viks I, Shum BO et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 2009; 139: 1255-1267.
26. Pinto LH, Lamb RA. Understanding the mechanism of action of the anti-influenza virus drug amantadine. Trends in Microbiology 1995; 3: 271.
27. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-835.
28. Hernandez JE, Adiga R, Armstrong R et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza a (H1N1) under an emergency IND program in the United States. Clinical Infectious Diseases 2011; 52: 695-706.
29. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Research 2002; 55: 307-317.
30. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328: 1272-1275.
31. Memoli MJ, Hrabal RJ, Hassantoufighi A et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clinical Infectious Diseases 2010; 50: 1252-1255.
32. Graitcer SB, Gubareva L, Kamimoto L et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerging Infectious Diseases 2011; 17: 255-257.
33. Seibert CW, Kaminski M, Philipp J et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. Journal of Virology 2010; 84: 11219-11226.
34. Memoli MJ, Davis AS, Proudfoot K et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. Journal of Infectious Diseases 2011; 203: 348-357.
35. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents and Chemotherapy 2006; 50: 1470-1479.
36. MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clinical Infectious Diseases 2008; 47: 236-241.
37. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco City cohort, ALIVE study. Science 1996; 273: 1856-1862.
38. Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Current Opinion in HIV and AIDS 2009; 4: 118-124.
39. Huang IC, Bailey CC, Weyer JL et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathogens 2011; 7: e1001258.
40. Lu J, Pan Q, Rong L et al. The IFITM proteins inhibit HIV-1 infection. Journal of Virology 2011; 85: 2126-2137.
41. Bushman FD, Malani N, Fernandes J et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathogens 2009; 5: e1000437.
42. Perez L, Carrasco L. Involvement of the vacuolar H(+)-ATPase in animal virus entry. Journal of General Virology 1994; 75(Pt 10): 2595-2606.
43. Guinea R, Carrasco L. Requirement for vacuolar proton-ATPase activity during entry of influenza virus into cells. Journal of Virology 1995; 69: 2306-2312.
44. Read EK, Digard P. Individual influenza A virus mRNAs show differential dependence on cellular NXF1/TAP for their nuclear export. Journal of General Virology 2010; 91: 1290-1301.
45. Satterly N, Tsai PL, van Deursen J et al. Influenza virus targets the mRNA export machinery and the nuclear pore complex. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 1853-1858.